Sugi Predict

Sugi Predict / Compounds / SCHEMBL2566968

SCHEMBL2566968

SCHEMBL2566968

Clc1ccc(Sc2ccccc2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 2/20 0.41
▸ MAOB P27338 2/20 0.41
▸ CHRNA7 P36544 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ HPGD P15428 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ NAPRT Q6XQN6 1/20 0.39
▸ KCNQ3 O43525 1/20 0.39
▸ KCNQ2 O43526 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP2A6 P11509 1/20 0.37
▸ TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30094521 1.00 MAOA (0.41) MAOAMAOBCHRNA7NPC1RAB9A
SCHEMBL16644 0.82 MAOA (0.42) MAOAMAOBL3MBTL1HTTNAPRT
SCHEMBL15200888 0.78 PIK3CD (0.62) CHRNA7NAPRTMAPTKDM4ESMN1; SMN2
SCHEMBL10834017 0.77 HPGD (0.50) MAOAMAOBCHRNA7NPC1RAB9A
SCHEMBL3151758 0.76 KCNQ3 (0.43) CHRNA7NPC1RAB9AL3MBTL1KCNQ3
SCHEMBL10732540 0.75 KDM4E (0.48) MAOAMAOBCHRNA7HPGDHTT
SCHEMBL11623859 0.75 MAOA (0.41) MAOAMAOBCHRNA7NPC1RAB9A
SCHEMBL7214352 0.75 MAOA (0.41) MAOAMAOBCHRNA7L3MBTL1HPGD
SCHEMBL10280707 0.75 PIK3CD (0.41) L3MBTL1NAPRTPOLBTDP1MAPT
SCHEMBL6109758 0.75 KCNQ3 (0.47) NPC1RAB9AKCNQ3KCNQ2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4536221-A1 TRIAZOLOPYRIDINE POLYMORPH A APM THERAPEUTICS 1, INC. (US) 2025-04-16 — — EP disclosed
WO-2023244539-A1 TRIAZOLOPYRIDINE POLYMORPH A APM THERAPEUTICS 1, INC. (US) 2023-12-21 — — WO disclosed
EP-3204007-B1 TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS APM THERAPEUTICS 1 INC (US) 2023-12-20 — — EP disclosed
US-11746108-B1 Triazolopyridine polymorph A APM THERAPEUTICS 1, INC. (US) 2023-09-05 — — US disclosed
US-11746108-B1 Triazolopyridine polymorph A APM THERAPEUTICS 1, INC. (US) 2023-09-05 — — US disclosed
US-11746108-B1 Triazolopyridine polymorph A APM THERAPEUTICS 1, INC. (US) 2023-09-05 — — US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 — — EP disclosed
US-20160096835-A1 TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS APM THERAPEUTICS 1, INC. 2016-04-07 — — US disclosed
EP-2382205-B1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI SA (FR) 2014-04-23 — — EP disclosed
US-8541455-B2 Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators SANOFI (FR) 2013-09-24 — — US disclosed
WO-2013123444-A1 SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN AMGEN INC. (US) 2013-08-22 — — WO disclosed
WO-2013123444-A1 SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN AMGEN INC. (US) 2013-08-22 — — WO disclosed
CN-102333769-A Derivatives of 2-pyridin-2-yl-pyrazol-3 (2H) -one, preparation thereof, and therapeutic use as HIF activators SANOFI AVENTIS 2012-01-25 — — CN disclosed
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-12-01 — — US disclosed
EP-2382205-A2 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI (FR) 2011-11-02 — — EP disclosed
WO-2010076524-A2 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS SANOFI-AVENTIS (FR) 2010-07-08 — — WO disclosed
US-4092321-A Process for the preparation of imidazo [1,2-a] pyridines MERCK & CO., INC. (US) 1978-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160096835-A1 TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, KCNJ11, KCNJ1 MAOA 858/4885MAOB 593/4885CHRNA7 1333/4885
US-20110294788-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS HIF1AN, HIF1A, EGLN2 MAOA 3751/4885MAOB 3702/4885CHRNA7 4753/4885
US-11746108-B1 Triazolopyridine polymorph A CYP3A5, CYP3A4, CYP3A43 MAOA 307/4885MAOB 447/4885CHRNA7 2257/4885
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 MAOA 3383/4885MAOB 2875/4885CHRNA7 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.